Cybin Inc. (CYBN)
- Previous Close
0.3699 - Open
0.3608 - Bid 0.3630 x 1200
- Ask 0.3655 x 1000
- Day's Range
0.3600 - 0.3729 - 52 Week Range
0.2100 - 0.7380 - Volume
1,642,073 - Avg. Volume
5,522,969 - Market Cap (intraday)
278.883M - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
www.cybin.comRecent News: CYBN
Performance Overview: CYBN
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYBN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYBN
Valuation Measures
Market Cap
286.84M
Enterprise Value
258.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.20
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.86
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.21%
Return on Equity (ttm)
-79.36%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-70.45M
Diluted EPS (ttm)
-0.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
39M
Total Debt/Equity (mrq)
0.30%
Levered Free Cash Flow (ttm)
-27.84M
Research Analysis: CYBN
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell